Skip to main content

Page last checked

GIP/GLP-1 dual receptor agonist (investigational) · safety

VK2735 side effects

The vk2735 side effects reported most often are nausea, constipation and vomiting. The full list is below, with the cited trial report cited at the bottom of the page.

Rarer, but worth being able to spot: atrial fibrillation and dehydration.

These effects tend to cluster at the start and after each dose increase, and to settle down while the dose stays the same.

VK2735 is an experimental weight-loss drug being tested as both a weekly injection and a daily pill. Sellers offer unapproved VK2735 to people seeking a newer weight-loss drug.

A short phase 2 injection trial reported average weight loss over 13 weeks. Two larger phase 3 injection trials are active. The pill remains earlier in testing.

Further down: the full list with frequencies · when to get medical help · questions

Medically reviewed by Jennifer Montecillo, MD · non-practicing medical reviewerReviewed 2026-08-16open the primary sources

At a glance

Common reactions listed

3

Serious reactions listed

1

Boxed warning

No label exists

Strongest source

Human trial

The counts show how many distinct reactions the cited trial report names. The percentages show how often a reaction appeared in a study group, not the chance that it will happen to you.

Common reactions

The full list, as reported across the available trial evidence. There is no approved label to read frequency bands off, so these are the trials’ own figures.

Common reactionstrial-reported
ReactionFrequency
NauseaTreatment-related event in 64 of 175 participants in the phase 2 safety population
ConstipationTreatment-related event in 37 of 175 participants in the phase 2 safety population
VomitingTreatment-related event in 22 of 175 participants in the phase 2 safety population

Serious reactions to watch for

These are rarer, and they are the ones clinicians monitor for. Seek medical care if you have symptoms.

Serious — monitorwarning/precaution
ReactionFrequency
Atrial fibrillation and dehydrationTwo serious events in one 5 mg participant; investigators judged them possibly and probably treatment-related

Human trialEvery reaction above comes from a cited trial. These are study findings, not instructions on what to take.

When to seek medical care

The trial report does not give a separate list of serious reactions. There is also no approved label. That gap does not mean serious reactions cannot happen. This compound has been studied in fewer people and for less time than an approved drug.

EmergencySome symptoms should not wait for an appointment. Call emergency services (911 in the US) if they are severe, getting worse fast, or involve trouble breathing, chest pain, fainting or confusion.

1Read deeperTiming, evidence limits, and product context

What the 13-week trial can—and cannot—show

The page above comes from a dose-finding study with 176 people. It tested weekly doses of 2.5 mg · 5 mg · 10 mg · 15 mg. The study shows what happened during that window. It may miss rare or later problems.

This page preserves 3 common reactions and 1 serious entry from that report. A missing reaction is outside this bounded record; it is not a result that the reaction cannot occur.

  • Investigational compound — no approved dose or prescribing label exists
  • The completed injection study lasted 13 weeks; the 78-week phase 3 trials have no result yet
  • Oral and injected VK2735 use different doses and are not interchangeable

VK2735 is not FDA-approved and has no prescribing label.

The published numbers are from a short dose-finding trial, not an approved schedule. Its tablet and injection programs use different doses and must not be read as one regimen.

Common questions

How long do vk2735 side effects last, and do they go away?

The 13-week trial report does not establish a set number of days for any reaction. It records whether an event occurred during the study, not a reliable personal countdown for when it will stop.

What are the most common vk2735 side effects?

Nausea, constipation and vomiting — the table above has the rest, each with its frequency band and source.

Does vk2735 have a boxed warning?

No, because a boxed warning is part of an FDA-approved label and vk2735 has no approved label. That reflects what regulatory review has and has not covered, not a finding that serious risks were looked for and ruled out.

Can the vk2735 dose be lowered if side effects are hard to tolerate?

That decision belongs to the prescribing clinician. No approved schedule exists for this compound, so there is no labeled framework for adjusting a dose. That leaves the prescriber as the only place the decision can sit.

Were hair loss, fatigue or constipation listed for vk2735?

In the 13-week report, constipation was listed; hair loss and fatigue were not. That is a statement about the paper’s recorded terms, not proof that an unlisted symptom cannot occur.

What should someone do about a serious vk2735 reaction?

Contact a clinician promptly, and emergency services if symptoms are severe or getting worse quickly. The section above describes what those reactions actually look like, so they can be spotted early rather than explained away.

Do the frequencies on this page mean the chance it happens to one person?

No. These figures describe groups in a study. A band shows how often a reaction appeared under that trial’s conditions. It cannot predict what will happen to one person.

Related

The schedule these reactions were recorded against, the comparisons, and the sourcing rules behind every grade on this page.

1primary source, each with the day we read it — open the documents used on this page